Acute Myelomonocytic Leukemia is a form of acute myeloid leukemia with the proliferation of myeloblasts and monoblasts. Even though Acute Myelomonocytic Leukemia is common form of pediatric cancer, the condition is rare otherwise. If left untreated, this form of cancer will progress very quickly. This disease produced immature white blood cells which do not allow healthy white bloods cells to function properly. Although there are treatments available such as multidrug chemotherapy and bone marrow transplants, the prognosis remains low with a survival rate of 35-60%.
Acute Myelomonocytic Leukemia Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Acute Myelomonocytic Leukemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 2755 products for the study of Acute Myelomonocytic Leukemia that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Acute Myelomonocytic Leukemia is also known as acute myelomonocytic leukemia, leukemia, acute myelomonocytic, leukemia myelomonocytic acute, leukemia.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.